PA8631801A1 - Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos - Google Patents

Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Info

Publication number
PA8631801A1
PA8631801A1 PA20058631801A PA8631801A PA8631801A1 PA 8631801 A1 PA8631801 A1 PA 8631801A1 PA 20058631801 A PA20058631801 A PA 20058631801A PA 8631801 A PA8631801 A PA 8631801A PA 8631801 A1 PA8631801 A1 PA 8631801A1
Authority
PA
Panama
Prior art keywords
conceptive
hemorragy
regimes
disruption
treatment
Prior art date
Application number
PA20058631801A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Sachse
Original Assignee
Schering Ag Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8631801(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag Schering Ag filed Critical Schering Ag Schering Ag
Publication of PA8631801A1 publication Critical patent/PA8631801A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
PA20058631801A 2004-04-30 2005-05-03 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos PA8631801A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
PA8631801A1 true PA8631801A1 (es) 2006-11-09

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058631801A PA8631801A1 (es) 2004-04-30 2005-05-03 Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos

Country Status (29)

Country Link
US (3) US8163721B2 (enExample)
EP (1) EP1747001B1 (enExample)
JP (4) JP2007535519A (enExample)
KR (4) KR20130022425A (enExample)
CN (1) CN103127156A (enExample)
AR (1) AR048722A1 (enExample)
AU (1) AU2005237255B2 (enExample)
BR (1) BRPI0510493A (enExample)
CA (1) CA2562296A1 (enExample)
CR (1) CR8709A (enExample)
DK (1) DK1747001T3 (enExample)
EA (2) EA031227B1 (enExample)
EC (1) ECSP066999A (enExample)
ES (1) ES2704999T3 (enExample)
HU (1) HUE041475T2 (enExample)
IL (1) IL178458A (enExample)
LT (1) LT1747001T (enExample)
MX (1) MXPA06012567A (enExample)
MY (1) MY151322A (enExample)
NO (1) NO341685B1 (enExample)
NZ (1) NZ586107A (enExample)
PA (1) PA8631801A1 (enExample)
PE (1) PE20060467A1 (enExample)
SG (2) SG10201701904TA (enExample)
SI (1) SI1747001T1 (enExample)
SV (1) SV2006002100A (enExample)
TW (1) TWI374735B (enExample)
UY (1) UY28875A1 (enExample)
WO (1) WO2005105103A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
KR20110045065A (ko) * 2008-09-16 2011-05-03 플레이텍스 프로덕츠, 엘엘씨. 월경 억제, 피임 및 호르몬 대체 요법을 위한 약제 및 이를 투여하는 방법
US9192614B2 (en) 2008-10-08 2015-11-24 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2343963B1 (en) 2008-10-08 2019-04-10 Agile Therapeutics, Inc. Transdermal delivery
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US10888518B2 (en) 2015-06-18 2021-01-12 Estetra Sprl Orodispersible tablet containing estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
JP6863547B2 (ja) 2015-06-18 2021-04-21 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
CN113750108B (zh) * 2015-06-23 2025-08-19 莱昂实验室制药股份有限公司 用于过重女性患者的基于屈螺酮的避孕药
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
FI3518933T4 (fi) 2016-09-30 2025-05-14 Sumitomo Pharma Switzerland Gmbh Menetelmiä kohtumyooman ja endometrioosin hoitamiseksi
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) * 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
WO1993013801A1 (en) 1992-01-17 1993-07-22 The Procter & Gamble Company Treatment for atherosclerosis
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) * 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
ES2223081T3 (es) * 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
PT1598069E (pt) * 1999-08-31 2009-07-20 Bayer Schering Pharma Ag Combinação farmacêutica de etinilestradiol e drospirenona para utilização como um contraceptivo
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) * 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) * 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) * 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
EA201200377A8 (ru) 2018-01-31
JP2013018787A (ja) 2013-01-31
US20050250747A1 (en) 2005-11-10
US20120202779A1 (en) 2012-08-09
AU2005237255A1 (en) 2005-11-10
ES2704999T3 (es) 2019-03-21
IL178458A (en) 2016-08-31
JP2007535519A (ja) 2007-12-06
SI1747001T1 (sl) 2019-02-28
UY28875A1 (es) 2005-11-30
NO341685B1 (no) 2017-12-18
TWI374735B (en) 2012-10-21
BRPI0510493A (pt) 2007-11-13
NZ586107A (en) 2012-05-25
NO20065499L (no) 2006-11-29
CN103127156A (zh) 2013-06-05
KR20150058555A (ko) 2015-05-28
IL178458A0 (en) 2008-04-13
WO2005105103A2 (en) 2005-11-10
EP1747001B1 (en) 2018-10-10
KR101812160B1 (ko) 2017-12-27
JP6153967B2 (ja) 2017-06-28
KR20070004919A (ko) 2007-01-09
JP2015187157A (ja) 2015-10-29
SV2006002100A (es) 2006-02-15
AU2005237255B2 (en) 2011-07-07
CR8709A (es) 2007-08-28
TW200603781A (en) 2006-02-01
ECSP066999A (es) 2006-12-29
KR20160150113A (ko) 2016-12-28
MY151322A (en) 2014-05-15
HUE041475T2 (hu) 2019-05-28
MXPA06012567A (es) 2006-12-15
EA200601908A1 (ru) 2007-04-27
PE20060467A1 (es) 2006-06-11
US8163721B2 (en) 2012-04-24
SG152288A1 (en) 2009-05-29
DK1747001T3 (en) 2019-02-04
LT1747001T (lt) 2019-01-25
WO2005105103A3 (en) 2006-09-08
JP2017048253A (ja) 2017-03-09
AR048722A1 (es) 2006-05-17
SG10201701904TA (en) 2017-05-30
KR20130022425A (ko) 2013-03-06
EA016625B1 (ru) 2012-06-29
JP6134491B2 (ja) 2017-05-24
CA2562296A1 (en) 2005-11-10
US20150174142A1 (en) 2015-06-25
EA031227B1 (ru) 2018-12-28
EA201200377A1 (ru) 2012-08-30
EP1747001A2 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
PA8631801A1 (es) Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
UY30304A1 (es) Moduladores de mglur5 i
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
UY30308A1 (es) Moduladores de mglur5 v
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
AR058505A1 (es) Combinaciones antineoplasicas de temsirolimus y malato de sunitinib
UY30306A1 (es) Moduladores de mglur5 iii
CL2011002962A1 (es) Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores.
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
PE20081881A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapicos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
UY30309A1 (es) Moduladores de mglur5 ii
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
BR112012014159A2 (pt) Combinações terapêuticas de teobromina e um anti-histamínico
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
NO20091628L (no) Kombinasjonsmedikament
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
BR112012011227A2 (pt) teobromina e agente combinado com outro antitussígeno não opióide e seu uso terapêutico
ECSP12012132A (es) Combinación de teobromina con un descongestivo y su uso para el tratamiento de la tos
BRPI0507463A (pt) uso de glufosfamide e gemcitabine , produto, e, combinação de glufosfamide e gemcitabine